Karan Desai MD Profile picture
Feb 1, 2022 5 tweets 9 min read Read on X
Join now as Dr. Mann gives a keynote on HF in 2022 in the era of SGLT2i #THT2022

“Predicting the future isn’t what it used to be” - Yogi Berra

In era where definitions of HF are becoming blurred, how do we define the role of therapies? A talk pertinent for all cardiologists
Followed by @NirUrielMD talking about the future of HF and pointing out this fantastic paper from @HRRosenblum on a device-based approach to ADHF w/ the DRI2️⃣P2️⃣S approach

Read paper here: ahajournals.org/doi/full/10.11…

@BrenerMickey @ersied727 @zilgiovineMD @tremartyn @AHajduczok
What a whirlwind tour by @GreggWStone on how the sausage gets made with HF device clinical trials

Look at all the factors: critical background on understanding how the evidence forms for the science we apply at the bedside

@mvaduganathan @FudimMarat @vbluml @SJGreene_md
Dr. @amorrismd giving a powerful talk on the under representation of diverse populations in HF trials, as well amongst investigators

Would encourage also to listen to this @CardioNerds episode with @shirleneobuobi on AHF therapy disparities: cardionerds.com/105-narratives…
Dr. @LindenfeldJoann breaking down how patient behavior and HF events changed during COVID-19 pandemic with data from Guide-HF #THT2022

What factors were at play leading to behavior modification: adherence? Diet?

Look at PAP data pre and during the pandemic

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Karan Desai MD

Karan Desai MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @karanpdesai

Feb 1, 2022
Join now at #THT2022 as @HFpEF describes the results of the REDUCE HF-LAP II trial: the largest contemporary HFpEF device based trial.

Not the exclusion criteria for patients that may not tolerate a right sided volume load were defined by resting RA pressure, TR severity and PVR
This was a sick population with a median resting PCWP > 18. Meticulous definition of HFpEF with Exercise hemodynamics

The LA strain was quite low in both arms and could that affect who would respond @RBPatelMD?
To the results: as predicted there was no change in incidence of CVD ☠️ btw sham and IASD, but there was also not a difference in 🏥.

What accounts for this result?

This was a sick population overall and wonder if those w/ low LA/RA reservoir affected likelihood to respond
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(